CSN Login
Members Online: 14

Of interest to those who are NED with BRCA mutation

Alexandra's picture
Posts: 1310
Joined: Jul 2012

New trial NCT01847274, sponsored by Tesaro, Inc. not yet recruiting. 

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, or PARP inhibitor. A Phase 1/2 monotherapy study has been completed in more than 100 patients with advanced solid tumors. Based upon the results of the Phase 1/2 study and published data from other trials of PARP inhibitors, TESARO plans to further evaluate niraparib at a dose of 300 milligrams once daily in each of two Phase 3 studies as a maintenance therapy in patients with platinum sensitive ovarian cancer and in germline BRCA breast cancer.

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study of niraparib as maintenance in platinum sensitive ovarian cancer patients who have either gBRCAmut or a tumor with high-grade serous histology and who have responded to their most recent chemotherapy containing a platinum agent. Niraparib or placebo (in a 2:1 ratio) will be administered once daily continuously during a 28-day cycle.


I emailed Tesaro today and received reply within minutes. I'm waiting for the list of local investigators, which I will post here once available.

lovesanimals's picture
Posts: 1343
Joined: Sep 2011

I do not know yet if I carry the BRCA mutation but I hope to find out soon after my August 1 meeting with a genetic counselor.


Subscribe with RSS
About Cancer Society

The content on this site is for informational purposes only. It is not a substitute for professional medical advice. Do not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition. Use of this online service is subject to the disclaimer and the terms and conditions.

Copyright 2000-2015 © Cancer Survivors Network